In the race to develop next-generation antibody therapies for solid tumors, antibody drug conjugates (ADCs) are surging, while T-cell engagers…
ORGANIZATION
Pharma Biz Leader Airs Concern over Effective Tax Hikes
Daiichi Sankyo President Joji Nakayama voiced his apprehension on January 7 over the ruling parties’ taxation reform plan for the next fiscal year, saying that it would be tantamount to a tax hike for some drug makers. The tax reform…
To read the full story
Related Article
- Pharma Leader Nakayama Hails Tax Plan, Says His New Year Remarks Misleading
January 15, 2015
- Ruling Parties Settle on 25%-Plus-5% Cap for R&D Tax Credit
January 5, 2015
ORGANIZATION
- JPMA Selected for Japan Program to Cut Carbon Emissions
July 23, 2025
- Industry Calls for More Tailored Govt Support on Drug Loss Product Development
July 16, 2025
- Japan Logs 11th Straight Year of Decline in Drug Reps, Voluntary Buyouts Likely a Major Factor
July 16, 2025
- Japan’s Generic Use Rate Reaches 86.5% in FY2024: JGA
July 7, 2025
- FPMAJ Confirms Regulatory Compliance Actions Completed for All Generic Drug Discrepancies
July 3, 2025
I recently attended a fantastic conference hosted by Prospection Japan, and one speaker, Dr. Joe Ledsam, really blew me away with his insights. He shared some truly fascinating developments about how AI is set to revolutionize healthcare, from how doctors…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…